Elevar Therapeutics announced that the US Food and Drug Administration has determined the PDUFA target approval date for its re-submitted new drug application for rivoceranib and carelizumab, which is intended for first-line systemic treatment of unresectable or metastatic hepatocellular carcinoma.

Zhitongcaijing · 3d ago
Elevar Therapeutics announced that the US Food and Drug Administration has determined the PDUFA target approval date for its re-submitted new drug application for rivoceranib and carelizumab, which is intended for first-line systemic treatment of unresectable or metastatic hepatocellular carcinoma.